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Introduction
Chronic HBV is the leading cause of  hepatocellular carcinoma and end-stage liver disease globally. 
Although a vaccine exists for HBV, there is no cure for the more than 270 million people who are chronical-
ly infected (1). A major barrier to a cure is the covalently closed circular DNA (cccDNA) that resides and 
persists in the nucleus of  every infected hepatocyte and that is the template for transcription of  viral RNAs 
(2). Because current antiviral treatments can control HBV replication in the hepatocyte cytoplasm but are 
ineffective at eliminating cccDNA, a major research priority is to develop curative therapies for HBV that 
affect this cccDNA reservoir (3). However, despite advances in cell culture and animal models, we have 
few insights into human HBV and regulation of  cccDNA transcription in the organ that it infects, the liver, 
especially in people receiving antiviral treatments.
Mature HBV virions contain relaxed circular DNA (rcDNA; Supplemental Figure 1; supplemental 
material available online with this article; https://doi.org/10.1172/jci.insight.140584DS1). Upon infecting 
the human hepatocyte, rcDNA uncoats and is converted into cccDNA by host DNA polymerases in the 
nucleus. Thereafter, a suite of  short and long viral mRNAs is transcribed by host RNA polymerase II. These 
viral transcripts are exported into the cytoplasm and either translated into structural, regulatory, or repli-
cative proteins, or packaged into new virions. Specifically, the long 3.5 kb RNA encodes for preC mRNA 
and pregenomic RNA (pgRNA); pgRNA is encapsidated as the template for the nascent virion or, as preC 
mRNA, is translated into the core and polymerase proteins that also compose the virion. The polymerase, 
a reverse transcriptase, converts the encapsidated pgRNA into rcDNA to restart the cycle of  infection. The 
most commonly used current antivirals are nucleos(t)ide analogs (NUCs), often dually active against HIV 
and HBV, which inhibit the reverse transcriptase, thereby interrupting the conversion of  pgRNA to rcDNA. 
There is no cure for the more than 270 million people chronically infected with HBV. Nucleos(t)
ide analogs (NUCs), the mainstay of anti-HBV treatment, block HBV reverse transcription. NUCs 
do not eliminate the intranuclear covalently closed circular DNA (cccDNA), from which viral RNAs, 
including pregenomic RNA (pgRNA), are transcribed. A key gap in designing a cure is understanding 
how NUCs affect HBV replication and transcription because serum markers yield an incomplete 
view of intrahepatic HBV. We applied single-cell laser capture microdissection and droplet digital 
PCR to paired liver biopsies collected from 5 HBV/HIV-coinfected persons who took NUCs over 2–4 
years. From biopsy 1 to 2, proportions of HBV-infected hepatocytes declined with adherence to NUC 
treatment (P < 0.05); we extrapolated that eradication of HBV will take over 10 decades with NUCs 
in these participants. In individual hepatocytes, pgRNA levels diminished 28- to 73-fold during NUC 
treatment, corresponding with decreased tissue HBV core antigen staining (P < 0.01). In 4 out of 5 
participants, hepatocytes with cccDNA but undetectable pgRNA (transcriptionally inactive) were 
present, and these were enriched in 3 participants during NUC treatment. Further work to unravel 
mechanisms of cccDNA transcriptional inactivation may lead to therapies that can achieve this in all 
hepatocytes, resulting in a functional cure.
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However, since NUCs act in the cytoplasm, they are not known to have direct effects on cccDNA forma-
tion or on viral transcription. Intriguingly, recent reports have shown that plasma HBV RNA levels (largely 
pgRNA) decline with NUCs, albeit more slowly than plasma HBV DNA levels that largely comprise rcDNA 
(4–11). In our recent cross-sectional study of  single hepatocyte analysis of  HBV in situ, intracellular pgRNA 
levels were lowest in people who had prolonged NUC therapy (12).
Taken together, these observations raise the hypothesis that transcription of  viral mRNA from cccDNA 
is downregulated during NUC treatment, but to test this directly requires advanced tools and liver speci-
mens obtained from people taking NUCs. We developed single-cell laser capture microdissection (scLCM) 
to study viral hepatitis in the liver (13, 14) and recently adapted it to study HBV (12). We designed and val-
idated specific primers and probes for different targets in the HBV genome and transcriptome, using droplet 
digital PCR (ddPCR) to quantify multiple viral targets with single-cell resolution. We applied the integrated 
platform to tissues collected from HBV/HIV-coinfected people who had core biopsies taken over the span 
of  2–4 years during NUC treatment through an ongoing natural history study. Our chief  aims were to 
quantify residual HBV infection in situ during NUC treatment and to test directly whether NUC treatment 
resulted in decreased HBV transcription.
Results
Participant characteristics. Participants in this study were all HIV coinfected because the parent Hepatitis 
B Research Network (HBRN) study focused on HBV/HIV coinfection (see Methods). From the tissues 
collected at Johns Hopkins University, 5 individuals with hepatitis B e antigen–positive (HBeAg-positive) 
chronic HBV, who had 2 biopsies, were selected for this study. They were selected based on a range of  plas-
ma HBV DNA levels (1.60–8.56 log10 IU/mL) at baseline (biopsy 1). Two individuals were not on HBV 
therapy at baseline but were on HIV therapy and had high plasma HBV DNA levels approximately 2 weeks 
before biopsy 1 (HB6 and HB2 had > 8 log10 IU/mL); 2 individuals were on dually active antiretroviral 
therapy (ART) containing NUCs with incomplete adherence and thus had intermediate HBV DNA levels 
(HB7 and HB3 had > 4 log10 IU/mL); and 1 individual was adherent to long-term NUC therapy with low 
levels of  HBV DNA at biopsy 1 (HB4) (Table 1). Among them, the median (min, max) age at baseline 
was 47 (range 28–53) years, and all 5 were male and Black. All 5 had controlled HIV; specifically, plasma 
HIV RNA in HB6, HB7, and HB4 was undetectable, was between 241 and 358 cp/mL in HB2, and was 
54 cp/mL in HB3. The median (min, max) baseline CD4+ T cell count was 390 (range 153–655) cells/μL. 
NUCs with antiviral activity against HBV between the 2 biopsies included tenofovir (as tenofovir disoproxil 
fumarate [TDF] or later as tenofovir alafenamide [TAF]) for 4 participants and entecavir (ETV) for HB2.
The time between biopsies ranged from 2.7 to 3.7 years. Because this was a registry and not a clini-
cal trial, adherence to ART and NUCs was emphasized by clinicians in the study team and routinely by 
providers, but participants were not removed from the study for nonadherence. Thus, the participants had 
different HBV virological outcomes. HB2 and HB4 had HBV virological suppression at the time of  biopsy 
2, and HB6 had low levels of  HBV DNA. HB7 and HB3 had residual viremia of  more than 2 log10 IU/mL, 
implying relative nonadherence to NUCs compared with the other participants.
scLCM and ddPCR for HBV nucleic acid targets. We performed scLCM and ddPCR on the 2 biopsies that 
had been archived from each of  these 5 participants (10 biopsies total). We isolated 100 to more than 200 
hepatocytes per person per biopsy, for a total of  2080 hepatocytes. In each hepatocyte, we quantified 3 
molecular viral targets (cccDNA, total HBV DNA, and pgRNA/preC mRNA; Supplemental Figure 2) 
and 1 host RNA (7SL) to assess for cell fragmentation, totaling more than 8000 separate measurements. 
Because ddPCR works on the principle of  measuring individual PCR reactions in 20,000 to 40,000 droplets 
per sample, our results are derived from more than 180 million individual PCR reactions. The number of  
individual PCR reactions per HBV target per cell confers immense precision to our estimates of  the abun-
dance of  each molecular target in each cell (see Methods and Supplemental Figure 3 for 95% confidence 
intervals around measurements).
HBV-infected hepatocytes persist for years despite NUCs. We first determined the proportion of  hepatocytes 
infected at baseline and the change in this proportion between biopsies. We defined a hepatocyte as infected 
if  any of  the 3 HBV-specific targets were detectable in the cell, with pgRNA detection being more sensitive 
for infection than the DNA markers (Supplemental Table 1). In biopsy 1, the proportion of  HBV-infected 
hepatocytes was more than 95% in HB6, HB2, and HB3; 79% in HB7; and a smaller but still significant 
proportion, 20%, in HB4, the individual on long-term NUCs with low/undetectable plasma HBV DNA 
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before biopsy 1 (Table 2 and Figure 1). In the 2 participants who initiated NUCs near the time of  biopsy 1, 
plasma HBV DNA levels dramatically declined between biopsies: from more than 8 log10 IU/mL at base-
line to 1.63 log10 IU/mL and undetectable in HB6 and HB2, respectively. Correspondingly, the proportion 
of  infected hepatocytes in HB6 declined from 100% to 79% and in HB2 from 98% to 38%. Plasma HBV 
DNA for HB7 declined between biopsies but was still detectable at biopsy 2 (2.89 log10 IU/mL), and the 
proportion of  infected hepatocytes decreased from 79% to 21%. HB3 had a plasma HBV DNA level of  
4.55 log10 IU/mL at biopsy 1 and 2.93 log10 IU/mL at biopsy 2, confirming poor adherence to NUCs, and 
the proportion of  infected hepatocytes did not change appreciably, from 99% to 96%. In contrast, HB4 had 
undetectable HBV viremia at and between both biopsies, and the proportion of  infected hepatocytes nota-
bly did not decrease but remained relatively stable at 20% to 31% over 3.6 years.
Next, we estimated the rates of  decline in the proportion of  infected hepatocytes: using mixed-effects 
modeling, we found a significant, but very slow, decline in the number of  infected hepatocytes over time 
(P < 0.05; Supplemental Table 2). We extrapolated from these values to the time it would take to eradicate 
HBV from the liver in these individuals, assuming constant adherence, the absence of  drug resistance, and 
a continuous log-linear decline in the number of  infected hepatocytes at the same rates as observed between 
biopsies (Figure 1). We also estimated the time to eradication of  HBV for a model therapy that would 
lead to loss of  90%, 80%, or 50% of  infected hepatocytes annually. We found that in the 5 people who we 
studied, continued antiviral therapy with NUCs would be unlikely to result in a cure because the median 
decline in the number of  infected cells was 10-fold every 20 years, implying it would take more than 10 
decades to attain a cure. Even with optimistic modeling of  a 90% annual loss of  infected hepatocytes, the 
time to eradication from the liver would be nearly 10 years.
NUCs are associated with decreased transcription of  cccDNA. As expected, NUC therapy decreased the propor-
tion of hepatocytes with total intracellular HBV DNA levels (P = 0.01; Supplemental Table 2) and levels of  
total HBV DNA levels per hepatocyte in people who also had observable decreases in plasma HBV DNA levels 
(P = 0.02; Supplemental Table 3 and Supplemental Figure 4). Next, to test our hypothesis that NUCs decrease 
cccDNA transcription, changes in pgRNA levels were determined in hundreds of hepatocytes between biop-
sies. Surprisingly, in individual hepatocytes, levels of intracellular pgRNA, which have not been described to be 
directly affected by NUCs (Supplemental Figure 1), decreased in the group as a whole, but not in all participants 
(P = 0.02; Table 2 and Supplemental Table 3), and more strikingly in those (HB6 and HB2) who had declines 
Table 1. Participant characteristics at baseline (biopsy 1) unless otherwise indicated
Participant ID HB6 HB2 HB7 HB3 HB4
Age, yr 53 46 47 28 51
Sex M M M M M
Race Black Black Black Black Black
CD4+ T cell count  
(cells/μL)
655 153 299 390 399
HIV RNA (cp/mL) <20 241–358 UD 54 UD
HBV DNA (log10IU/mL) 
at biopsy 1
8.49 8.56 4.15 4.55 1.60
Interval before biopsy ~3 weeks ~2 weeks ~3 weeks ~6 weeks ~6 weeks
HBV DNA (log10IU/mL) 
at biopsy 2
1.63 UD 2.89 2.93 UD





ABC/DTG/DRV/r/ETV TDF/FTC/ATV/r TDF/FTC/ATV/r TDF/FTC/DRV/r/RAL
Duration of HBV-active 
ART at biopsy 1
2 weeks Stopped TDF 11 months 
before biopsy
3.5 years but 
intermittent 
compliance
4 years but intermittent 
compliance. Restarted 





3.6 3.6 3.7 2.7 3.6
All participants were HBeAg+. ABold text for ART indicates HBV-active antivirals. UD, undetectable; TDF, tenofovir disoproxil fumarate; FTC, emtricitabine; DTG, 
dolutegravir; RPV, rilpivirine; ABC, abacavir; DRV/r, darunavir boosted with ritonavir; ATV/r, atazanavir boosted with ritonavir; RAL, raltegravir; ETV, entecavir.
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in plasma and intracellular HBV DNA and were adherent to NUCs (P = 0.0001). Specifically, pgRNA levels 
in HB6 decreased from a median (min, max) of 2.91 (0.60–3.53) log10 cp/cell to 1.04 (undetectable–2.42) log10 
cp/cell (Table 2 and Figure 2A) and in HB2 decreased from a median (min, max) of 1.45 (undetectable–2.24) 
log10 cp/cell to below the limit of detection (undetectable–2.02) log10 cp/cell (Table 2 and Figure 2B). The pro-
portion of hepatocytes that contained pgRNA also declined for HB6 and HB2 (P < 0.01; Supplemental Table 
2). For HB7, who had incomplete adherence but still had a plasma HBV DNA decline from 4.15 to 2.89 log 
IU/m, the median (min, max) pgRNA declined from 1.08 (undetectable –3.47) log10 cp/cell to undetectable 
(undetectable–0.60) log10 cp/cell (Table 2 and Figure 2C). Two participants had relatively stable pgRNA levels: 
HB4, who had low or undetectable plasma HBV DNA throughout, and HB3, who had incomplete adherence 
and whose plasma HBV DNA did not decline substantially (Table 2 and Figure 2, D and E).
Although these results were consistent with a change in viral transcriptional activity during NUC 
therapy, the alternate possibility is that NUCs led to diminished reinfection and replenishment of  cccD-
NA, and thus the amount of  pgRNA decreased proportionally. However, there were no significant 
changes in the proportion of  hepatocytes containing cccDNA (Supplemental Table 2) or in the number 
of  cccDNA molecules per hepatocyte between the paired biopsies (Table 2 and Supplemental Table 
3), although the range of  cccDNA did appear to change for HB6 (Supplemental Figure 5). To confirm 
these observations, we calculated a transcriptional index for each cell as the number of  pgRNA copies 
per cccDNA in a given cell (Table 2 and Figure 3). We found that the median transcriptional index 
in biopsy 1 for participant HB6 was 533 (min 1, max 3145) and at biopsy 2 was 16 (min 0, max 264). 
Similar declines in the transcriptional index were observed in HB2 and HB7 with observable declines 
in plasma HBV DNA, strongly supporting that there was a decline in HBV transcription with NUC 
therapy in those who also had suppressed plasma HBV DNA levels (Table 2 and Figure 3). The wide 
range of  transcriptional indexes within an individual also supported variability in transcription between 
hepatocytes with the extreme of  no transcription (transcriptional index of  0). Indeed, for 4 individuals 
(HB6, HB2, HB7, HB4), we found evidence of  infected cells with detectable cccDNA but undetectable 
pgRNA (cccDNA+/pgRNA–). These cells, which were either transcriptionally silent or transcriptionally 
inactive, were a larger proportion of  all infected cells in people with demonstrated NUC adherence at 
biopsy 2 (Table 2). Surprisingly, 1 of  those individuals, HB4, who had suppressed HBV viremia at both 
biopsies, had an increase in the proportion of  cells that were transcriptionally inactive from 1.2% to 
7.8%. Importantly, as a proportion of  only infected cells, these transcriptionally inactive cells increased 
in HB4 from 5.8% to 25.5%, suggesting that long-term NUC adherence increases the proportion of  
infected cells that are transcriptionally inactive.
Table 2. Change in intracellular HBV markers and transcriptional activity between biopsies
Participant ID HB6 HB2 HB7 HB3 HB4
Biopsy no.  





















Plasma HBV DNA (log10IU/mL) 8.49 1.63 8.56 UD 4.15 2.89 4.55 2.93 1.60 UD
Intracellular markers
 Hepatocytes infected (%)A 100 79 98 38 79 21 99 96 20 31






































 cccDNA (cp/cell)B 1 (1, 10) 1 (0, 4) 1 (0, 4) 0 (0, 16) 1 (0, 4) 0 (0, 4) 1 (0, 10) 1 (0, 4) 0 (0, 2) 0(0, 4)



















 Transcriptionally inactiveD  
 (% all cells) 0 0.5 0.8 0.6 1.1 5.6 0 0 1.2 7.8
 Transcriptionally inactiveD  
 (% infected cells) 0 0.6 0.8 1.5 1.4 26.3 0 0 5.8 25.5
AA hepatocyte was defined as infected if any of the 3 viral targets was detectable in the cell. BMedian (min, max); the values reported are for cells for which 
measurements were made for all 3 viral targets. CTranscriptional index is calculated by dividing the number of copies of pgRNA in 1 cell by the number of 
copies of cccDNA in the same cell. DTranscriptional inactivity was defined in cells in which cccDNA was detectable, but pgRNA was not detectable.
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Declines in hepatitis B core antigen production correlate with decreased pgRNA transcription during NUC treat-
ment. Since pgRNA also encodes for the HBV core protein via preC mRNA, we hypothesized that pgRNA 
levels would correlate with the amount of  hepatitis B core antigen (HBcAg) in liver tissue. Using IHC for 
staining HBcAg and hepatitis B surface antigen (HBsAg) as a positive control, the proportion of  hepato-
cytes with HBcAg staining correlated with the proportion of  cells that had detectable pgRNA (r = 0.83; P 
= 0.0061; Supplemental Table 4 and Figure 4, A and B). We noted that pgRNA detection by ddPCR was 
more sensitive than HBcAg detection, as there was a range of  detection of  pgRNA when HBcAg stained 
less than 5% of  hepatocytes. Taken together, our scLCM/ddPCR results and IHC strongly indicated that 
HBV underwent transcriptional regulation of  its cccDNA such that pgRNA (which encodes for precore 
and core antigens and is the genomic template for new virions) diminished with NUCs.
Discussion
In this intensive longitudinal study of  intrahepatic single-cell HBV replication, using tissues collected 
from HBV/HIV-coinfected people taking ART containing NUC therapy, we performed scLCM on more 
than 2000 hepatocytes and collected ddPCR data from more than 180 million individual PCR reactions. 
We synthesized these data to report 2 observations. First, we found that even with adherence to a potent 
antiviral regimen currently available, including tenofovir, the loss of  HBV-infected hepatocytes was neg-
ligible. In addition, we found that NUC-mediated suppression of  plasma HBV DNA levels was also 
associated with a decrease in intracellular pgRNA levels without a proportionate decrease in cccDNA, 
strongly suggesting viral transcriptional regulation during NUC treatment, a likely unique finding in 
vivo. These results underscore the main challenges in curing chronic HBV with NUCs but also offer clues 
as to how HBV may persist despite NUC therapy.
Single-cell quantification of  the burden of  HBV infection in the liver has been challenging and, to our 
knowledge, this is the first investigation of  single-cell HBV infection in longitudinal liver biopsies. However, 
several studies have explored the rate at which HBV can be cleared from the liver during NUC therapy. Using 
bulk liver tissue, the decline in cccDNA in monoinfected persons was estimated at 0.80 log10 copies/cell after 
48 weeks of  NUC therapy (15). Similar results have been reported in HBV/HIV-coinfected people during 
tenofovir therapy (16). Animal models have shown variable rates of  cccDNA decline with NUC therapy. 
A model of  duck HBV infection demonstrated rapid cccDNA decline with NUC therapy that ultimately 
reached a plateau (17). Similarly, cccDNA decline in woodchuck HBV with NUC therapy has been described 
Figure 1. HBV eradication from the liver is slow. (A) The proportion of infected hepatocytes for each participant at each biopsy is shown. Points indicate 
when each biopsy was taken; the line indicates the inferred trajectories of the proportion infected, extrapolated from the proportions at each point; 95% 
confidence intervals are shown in the light shaded portion around each line. (B) The log10(number of infected hepatocytes) was estimated from the propor-
tion of infected hepatocytes that was calculated at each liver biopsy in the 5 participants. The changes in log10(number of infected hepatocytes) for each 
participant were extrapolated to estimate when the liver could be considered eradicated of all infection. Extrapolated values are shown by dotted lines. For 
comparison, 90%, 80%, and 50% annual cure rates (i.e., the number of HBV-infected hepatocytes that are cleared each year) are shown as dashed lines. 
DAART, dually active antiretroviral therapy.
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Figure 2. Virologic control of HBV with NUCs is accompanied by 
reduced transcription of pgRNA. Shown in dashed lines and on the left 
axes are the plasma HBV DNA levels spanning the interval between the 
2 core liver biopsies for (A) HB6, (B) HB2, (C) HB7, (D) HB3, and (E) HB4. 
Shown in box plots and on the right axes are the aggregated single-cell 
pgRNA levels at the first (red box-and-whisker and individual points) 
and second (blue box-and-whisker and individual points) biopsies. For 
each point in the box plots, 20,000–40,000 individual PCRs were per-
formed. The lower limits of detections for plasma HBV DNA (shown in 
purple) and intracellular pgRNA (shown in green) are also shown. Medi-
an log10 pgRNA copies/cell are shown in the legend for each participant.
7insight.jci.org   https://doi.org/10.1172/jci.insight.140584
R E S E A R C H  A R T I C L E
as quite slow compared with intrahepatic total HBV DNA loss (18). In vitro loss of  cccDNA is similarly 
slow (19). Our results are not directly comparable to these prior reports because we quantified infected cells. 
By focusing on the infected cell, we can estimate the time to loss of  all infected cells, the sine qua non of  an 
eradicative cure. In the case of  a functional cure, the infected hepatocyte is still the relevant unit since it is 
likely that the biology of  the hepatocyte governs the transcriptional activity of  the cccDNA reservoir within.
Several recent reports describing the kinetics of  HBV RNA in blood during NUC treatment support 
our findings of  NUCs affecting transcriptional regulation. It is first important to note that plasma HBV 
RNA is thought to be encapsidated intracellular HBV RNA (20). Plasma HBV RNA has been increasingly 
used as a novel biomarker of  chronic hepatitis B (CHB). Intriguingly, numerous investigations consistently 
find that plasma HBV RNA levels decrease during NUC treatment, albeit at intermediate rates between 
rapidly declining plasma HBV DNA levels and the very slow rates of  HBsAg decline. Persons with CHB 
who received NUCs for 4–64 months experienced declines in plasma HBV RNA levels between 3 and 6 
months after initiation of  treatment (4). Plasma HBV RNA levels are correlated with both plasma HBV 
DNA levels and with HBsAg levels and appear to predict HBeAg and HBsAg loss in some patients. There 
is a close relationship between plasma HBV RNA levels and intrahepatic HBV RNA levels, which adds 
support to our findings (21, 22).
Plasma HBV RNA levels have been shown to predict response to pegylated interferon (8, 11, 23) and 
to NUC interruption (6, 7, 9, 10): persons with suppressed plasma HBV DNA and RNA levels are less 
likely to develop HBV reactivation after NUC interruption than persons with suppressed HBV DNA levels 
but detectable HBV RNA levels. One potential explanation for this finding is that persons with suppressed 
HBV RNA levels might have infected cells that are transcriptionally inactive, and thus less likely to reacti-
vate. Notably, one group reported that detectable blood HBV RNA levels were found in people who later 
experienced HBV reactivation, suggesting that silent cccDNA can be stimulated to actively transcribe, thus 
beginning anew a cycle of  viral replication and, consequently, hepatitis (i.e., transaminase elevations). It is 
tantalizing to consider transcriptional regulation of  cccDNA as the linchpin of  a functional cure. Indeed, 
siRNAs to the HBV S gene have recently resulted in prolonged suppression of  blood HBsAg levels (24). 
Figure 3. The transcriptional index is reduced when plasma HBV DNA levels decrease. The transcriptional index was calculated for each cell by dividing 
the number of pgRNA copies by the number of cccDNA copies in the same cell (x axis). Violin plots (showing medians, IQRs, distributions, and individual 
points) show the transcriptional index for every cell, stratified by participant, in the first (salmon) and second (light blue) biopsies. Shown above each pair 
of violin plots are the contemporaneous plasma HBV DNA levels (above) and the number of examined hepatocytes (below). Values are log10 transformed; 
therefore, hepatocytes that did not contain pgRNA or cccDNA are not shown.
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It is possible, therefore, that the transcriptionally inactive or silent cell that we have identified in the liver 
is both the goal of  a functional cure strategy, and potentially the reservoir from which HBV reactivates. 
Thus, understanding how HBV transcription is regulated, and how it can be durably suppressed, may be a 
key step in developing an HBV cure.
HBV transcriptional regulation has been extensively reviewed elsewhere (25). There are numerous tran-
scription factors and 2 viral enhancers that could be modified during NUC treatment. Briefly, we conjecture 
that multiple aspects of  the biology of  the infected cell should be explored in vivo, including innate immune 
Figure 4. HBV core protein expression is reduced during NUC treatment and corresponds with the intracellular 
transcriptional index. (A) IHC was used to stain for HBcAg and HBsAg in first and second biopsies for all 5 participants. 
Shown are representative micrographs for HB2, alongside hematoxylin and eosin staining. (B) The amount of staining 
for HBcAg was quantified in each biopsy by a hepatopathologist who was blinded to participant identity (Supplemen-
tal Table 4). Shown is the correlation between the midpoint percentage of HBcAg-stained cells and the percentage of 
hepatocytes that contained detectable pgRNA, indexed by participants and time point. Data for HB3 biopsy 2 are not 
shown because less than 30% of tissue was available for staining; this slide was not further analyzed. Spearman’s 
correlation coefficients and associated P values are shown in B.
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signaling, microRNA suppression, positive and/or negative feedback from viral gene products, and epi-
genetic modifications. We further conjecture that although all types of  transcriptional regulation may cul-
minate in epigenetic silencing, proximate molecular causes, or “switches,” should be sought to understand 
how to design therapies that silence HBV effectively.
Our study had several limitations that warrant mention. Our sample size is clearly limited and only 
includes Black males. This was largely because of  the demographics of  the enrollment area. The limited 
sample size, however, is offset by intensive study of  each individual at 2 time points, providing a more 
comprehensive analysis of  intrahepatic HBV in these participants, and by the consistency in the findings. 
Moreover, our findings are clearly consistent with larger studies characterizing plasma HBV RNA kinetics 
during NUC therapy. Ours is the first study, to our knowledge, to quantify HBV replication at the single-cell 
level during a longitudinal perturbation. In that regard, we have demonstrated the feasibility of  similarly 
designed translational studies to examine HBV biology during a therapeutic intervention. It is also worth 
remarking that we only studied tissues from HBV/HIV-coinfected people. Although studies of  coinfection 
are important for this neglected special population, one question that arises from this approach is whether 
our findings are generalizable to HBV-monoinfected people. Most participants had preserved CD4+ T cell 
counts, supporting that our results are generalizable. However, while we acknowledge that our study should 
be repeated in HBV-monoinfected people, we also note that the importance of  our findings, their consisten-
cy, and their explanatory value to the condition of  HBV monoinfection outweigh the sample selection. It 
is also important to note that among our assays, the pgRNA assay appeared to be most sensitive. Thus, it is 
possible that cccDNA rates declined more robustly than observed.
In closing, we report here that integrated scLCM and ddPCR can be applied to HBV in situ to reveal a 
dynamic viral landscape (viroscape) during antiviral treatment. We estimated the number of  infected cells 
and the change in the number of  infected cells with NUC therapy, quantifying the gap between current strat-
egies and ideal eradicative cure scenarios. We also demonstrated that HBV transcription of  pgRNA declined 
nearly 100-fold during NUC therapy. We conclude that durable transcriptional silencing may be an effective 
strategy to achieve a functional cure, although there remains the possibility of  HBV reactivation. Further 
work is needed to understand HBV transcriptional regulation during treatment as a potential route to a cure.
Methods
Participant selection. Liver tissues were obtained from 5 people with chronic HBV (defined as HBsAg posi-
tive) and HIV-1 coinfection (defined as HIV-1 antibody positive), through the HIV-HBV Cohort Ancillary 
Study of  the HBRN (R01 DK094818; ClinicalTrials.gov NCT01924455). Through the HBRN registry, 
paired core liver biopsies were collected by ultrasound-guided biopsy within an interval of  2–4 years. At the 
time of  procurement, all tissues were placed in neutral cutting media and stored in liquid nitrogen until use.
Plasma HBV DNA levels. Plasma HBV DNA levels were determined by the Johns Hopkins Clinical 
Laboratory.
scLCM, DNA/RNA extraction, and reverse transcription. scLCM was performed on more than 2000 hepatocytes 
from all subjects, separately isolating each hepatocyte into individual microfuge tubes containing proprietary 
lysis buffer (ZR-Duet DNA/RNA MiniPrep kit, Zymo Research), as we have done previously (12). DNA and 
RNA from each hepatocyte were extracted separately according to the manufacturer’s protocol, except using 
Zymo-Spin IC columns and eluting in 22 μL of nuclease-free water. RNA extracts were treated with DNase I 
in-column during the extraction, and SuperScript IV First-Strand Synthesis System (Thermo Fisher Scientific, 
18091050) was used to synthesize complementary DNA (cDNA) according to the manufacturer’s protocol.
Molecular assay characteristics for HBV DNA replicative forms. We adapted primers and probes for total 
HBV DNA, cccDNA, and pgRNA to a ddPCR format that we have previously validated for low-abun-
dance targets (Supplemental Figure 2) (15, 26, 27). We used enzymatic treatments with exonuclease I/III 
treatments (exo I/III; New England Biolabs, M0293 and M0206) to diminish the false detection of  rcDNA 
as cccDNA by cleaving DNA that is not fully circular (28). We have previously shown that this method 
clears all of  the noncircular HBV DNA (rcDNA and integrated DNA) before analysis (12).
ddPCR. DNA extract from each cell was divided equally in 2 portions: each one-half  portion of  DNA 
extract (11 μL) from each cell was used to quantitate either total HBV DNA or cccDNA. One-quarter portion 
of  cDNA (11 μL) was used to quantitate pgRNA. DNA and cDNA were solubilized in water with Bio-
Rad ddPCR Supermix for Probes (No dUTP) (1863023/1863024/1863025), primers, and fluorescent probes, 
and loaded into droplet generation cartridges. Subsequently, single samples were partitioned with oil to form 
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thousands of  droplets through microfluidics channels. Droplet-partitioned samples were then transferred to 
96-well plates, and PCR was performed as we have described previously (12). Plates were then read by the 
QX200 Droplet Digital PCR System (Bio-Rad), an endpoint fluorescence detection reader, according to the 
manufacturer’s protocol. As a quality control measure, 2 cells were excluded from further analysis because 
fewer than 10,000 droplets were formed from their cellular extracts. The concentration of  target in a sample 
was calculated using Poisson statistics as a function of  the number of  droplets that were positive for the PCR 
product and the number of  droplets that were negative for the product. Since the sensitivity of  ddPCR is par-
tially constrained by the total number of  droplets in which PCR was performed, we performed the assay twice 
for total HBV DNA and cccDNA to lower the limit of  detection. Consequently, the lower limits of  detection 
for total HBV DNA and cccDNA, when calculated, were 2 copies per cell and for pgRNA were 4 copies/cell, 
similar to what was reported by Laras et al. (27). As a means of  calibration, ddPCR was run with 4 polyeth-
ylene naphthalate membrane controls (DNA negative) per 100 hepatocytes, assigning any cell with this value 
or less as having no HBV. Using the raw numbers of  positive and negative droplets for each cell, we calculated 
95% confidence intervals, conservatively estimating the error for each quantity (Supplemental Figure 2).
Real-time reverse transcription quantitative PCR. Real-time reverse transcription quantitative PCR was used 
to detect 7SL, an abundant cytoplasmic RNA that is used to normalize the amount of  captured cytoplasm 
for each hepatocyte. 7SL was quantified in cDNA using PrimeTime Gene Expression Master Mix (Inte-
grated DNA Technologies, 1055770) and compared with a cloned 7SL standard as we have done previously 
(13). Captures with less than 1 standard deviation below a standard negative control measurement were 
excluded from the final analysis to avoid false quantification of  cell fragments. Negative controls for cellular 
material included empty portions of  the same slides that did not contain liver tissue.
IHC. Glass slides were stained at our institution with IHC stains for hepatitis B core and surface anti-
gens. Slides were baked at 95°C for 36 minutes and loaded onto a BenchMark ULTRA slide stainer (Ven-
tana Medical Systems). Briefly, stains were deparaffinized and heat-induced epitope retrieval was achieved 
with Tris-based ULTRA CC1 solution (Ventana Medical Systems).
For HBsAg staining, a polyclonal rabbit antibody against HBcAg (Abcam, ab115992) was used at a 
dilution of  1:300 and incubated for 32 minutes. Detection was achieved using an ultraView Universal DAB 
detection kit (Ventana Medical Systems), and slides were counterstained, dehydrated, and mounted. Tissue 
with known hepatitis B core antigen expression was used as a positive control.
For HBsAg staining, a predilute monoclonal mouse antibody against HBsAg (Cell Marque, A10F1) 
was used and incubated for 28 minutes. Detection was achieved using an iVIEW DAB detection kit (Ven-
tana Medical Systems), and slides were counterstained, dehydrated, and mounted. Tissue with known 
hepatitis B surface antigen expression was used as a positive control.
Statistics. Because ddPCR relies on thousands of  negative droplets in a measurement to determine con-
centration, 95% confidence intervals were calculated when the standard error of  the mean was unusable 
because of  extreme outlier values. We employed 3 calculations: A = 2r + 3.84; B = 1.96 × [3.84 + (4r(n – 
r)/n)]½; C = 2(n + 3.84), where n is the total number of  droplets and r is the number of  positive droplets in 
a single ddPCR reaction. The 95% lower and upper confidence intervals were then calculated as (A – B)/C 
and (A + B)/C, respectively.
We analyzed the decay of  infected cells with different genomic material components using mixed-ef-
fects models. In this approach, we used all the data together to fit a regression model, where we assumed 
that participants were a sample from a given population and entered the model as a grouping (or ran-
dom) effect. Time between biopsies was the independent variable, such that we calculated the decay of  
hepatocytes containing a given viral target (total HBV DNA, cccDNA, or pgRNA) per year. We also used 
mixed-effects models to analyze the decay of  different viral targets per infected cell, using the median levels 
of  cp/cell. Here, we calculated the decay of  each viral target per year.
Transcriptional indices were compared between biopsies 1 and 2 using a pairwise Wilcoxon’s rank sum 
test in R (“pairwise.wilcox.test”). P values less than 0.05 were deemed significant. Spearman’s correlation 
coefficients were calculated in R (“stat.cor”; method = Spearman) comparing the percentage of  hepato-
cytes stained positive for HBcAg to the percentage of  hepatocytes positive for pgRNA extrapolated from 
grid measurements. Any r values approaching 1 with a P value less than 0.05 were deemed significant.
Study approval. The use of  tissues from humans for the present study was reviewed and approved by the 
Office of  Human Subjects Research Institutional Review Board, IRB-3, Baltimore, Maryland, USA. All 
participants gave written informed consent for use of  their tissues for research purposes through the HBRN.
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